Oct 4 (Reuters) - The European drugs regulator said on

Friday it was reviewing anti hair-loss drugs, including

Organon's Propecia, for the potential risk of suicidal

thoughts and behaviour associated with them.

The European Medicines Agency said it would recommend

whether the marketing authorisations for the drugs should be

withdrawn, suspended or maintained across the region following

its review.

Oral anti-baldness drugs, which contain finasteride and

dutasteride, have a known risk of psychiatric side effects,

including depression.

These drugs are sold under the brand name Propecia and

Avodart by Organon, a Merck ( MRK ) spin-off, and British

drugmaker GSK, respectively, but also have generic

versions available in the market.